Germany deal with CureVac and GSK primed for 80M mRNA vaccines a year
If there’s another pandemic, the German government is determined not to be caught off-guard when it comes to manufacturing vaccines.
CureVac and GSK have signed a deal to supply Germany with mRNA vaccines for pandemic preparedness going forward. After a setup period that will last no longer than two years, the contract gives Germany’s government access to the CureVac manufacturing capacity until 2029.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.